Publications by authors named "L Tinti"
Unraveling vulnerabilities in chronic lymphocytic leukemia (CLL) represents a key approach to understand molecular basis for its indolence and a path toward developing tailored therapeutic approaches. In this study, we found that CLL cells are particularly sensitive to the inhibitory action of abundant serum protein, apolipoprotein E (ApoE). Physiological concentrations of ApoE affect CLL cell viability and inhibit CD40-driven proliferation.
View Article and Find Full Text PDFArticle Synopsis
- This text refers to a correction made to an article identified by its DOI (Digital Object Identifier) 10.15420/ecr.2024.03.
- The correction is likely aimed at addressing inaccuracies or clarifying information presented in the original article.
- Such corrections are important in academic publishing to maintain the reliability and integrity of scientific literature.
Background: Detection of myocardial bridge (MB) at angiography suggests it has a role in ischaemic-related symptoms in patients with angina without obstructive coronary artery disease. However, evidence that MB may cause myocardial ischaemia is limited.
Methods: We studied 41 patients with MB of the left anterior descending coronary artery and otherwise normal coronary arteries.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascular risk and/or candidate to receive cardiotoxic therapies.
View Article and Find Full Text PDFBackground: More than 200 clinical trials have been performed worldwide in ALS so far, but no agents with substantial efficacy on disease progression have been found.
Objective: To describe the methodological quality of all clinical trials performed in ALS and published before December 31, 2022.
Methods: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta Analyses.